Moreover, the therapeutic horizon for EC might be expanded by targeting the integrin β1/FAK/MYC signaling axis using small molecular antagonists such as defactinib and 10058-F4 or through a selective antibody blockade of integrin β1, given their pronounced effect in curtailing EC's cancer stemness attributes. The gene discussed is PTK2; the disease is cancer.